Compare UPWK & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPWK | WVE |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2018 | 2015 |
| Metric | UPWK | WVE |
|---|---|---|
| Price | $13.18 | $13.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 16 |
| Target Price | $22.33 | ★ $30.44 |
| AVG Volume (30 Days) | ★ 4.7M | 2.9M |
| Earning Date | 05-11-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $787,784,000.00 | $3,704,000.00 |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $13.32 | $15.93 |
| P/E Ratio | $15.84 | ★ N/A |
| Revenue Growth | 2.40 | ★ 149.43 |
| 52 Week Low | $11.13 | $5.28 |
| 52 Week High | $22.84 | $21.73 |
| Indicator | UPWK | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 29.80 | 46.21 |
| Support Level | $12.73 | $12.52 |
| Resistance Level | $14.19 | $13.36 |
| Average True Range (ATR) | 1.17 | 0.74 |
| MACD | -0.47 | 0.01 |
| Stochastic Oscillator | 6.65 | 28.78 |
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to clients.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.